As of November 10, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Cabaletta Bio Inc. The largest reported stake is T. Rowe Price Investment Management, Inc.'s, at 13.1%. 35 filings are on record since July 16, 2025 (Schedule 13G/A, November 6, 2026).
Sell to companies like Cabaletta Bio Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: T. Rowe Price Investment Management, Inc. · Sole voting: 28,048,173 · Shared voting: 0 · Sole dispositive: 28,138,417 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-06
- · Holder: T. Rowe Price Investment Management, Inc. · Percent: 8% · SCHEDULE 13G/A
- · Reporting person: Vanguard Capital Management · Sole voting: 1,042,425 · Shared voting: 0 · Sole dispositive: 8,187,183 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-30
- · Reporting person: BlackRock, Inc. · Sole voting: 12,756,356 · Shared voting: 0 · Sole dispositive: 13,013,495 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
- · Reporting person: Bain Capital Life Sciences Opportunities III, LP · Sole voting: 0 · Shared voting: 17,241,445 · Sole dispositive: 0 · Shared dispositive: 17,241,445 · SCHEDULE 13G/A, 2026-08-14
Cabaletta Bio Inc has 35 Schedule 13D or 13G filings on record since 2025-07-16. 8 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13.1% | 28,138,417 | SCHEDULE 13G/A, 2026-11-06 | 2026-10-31 |
| Jennison Associates LLC | 11.4% | 24,267,980 | SCHEDULE 13G/A, 2026-06-04 | 2026-05-29 |
| Prudential Financial Inc | 11.4% | 24,267,980 | SCHEDULE 13G/A, 2026-06-05 | |
| Bain Capital Life Sciences Opportunities III, LP | 9.99% | 17,241,445 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Adage Capital Management, L.P. | 8.43% | 14,174,758 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| BlackRock, Inc. | 7.7% | 13,013,495 | SCHEDULE 13G/A, 2026-10-27 | 2026-09-30 |
| Cormorant Asset Management, LP | 5.95% | 10,000,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Norges Bank | 5.38% | 8,775,653 | SCHEDULE 13G, 2026-08-12 | 2026-06-30 |
| Alyeska Investment Group, L.P. | 4.67% | 4,500,000 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| The Vanguard Group | 3.83% | 3,450,727 | SCHEDULE 13G/A, 2025-07-29 | 2025-06-30 |
| Vanguard Capital Management | 3.79% | 8,187,183 | SCHEDULE 13G/A, 2026-10-30 | 2026-09-30 |
| 3.4% | 3,150,275 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 | |
| 3.3% | 3,034,499 | SCHEDULE 13G/A, 2025-08-11 | 2025-06-30 | |
| Millennium Management LLC | 1.3% | 2,068,491 | SCHEDULE 13G/A, 2026-07-23 | 2026-06-30 |
Holding shares or following this stake? See who's behind Cabaletta Bio Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Cabaletta Bio Inc and the records around it.
Cabaletta Bio Inc elsewhere on the record
Companies that share a holder
- Bain Capital Life Sciences Opportunities III, LP also filed stake reports on 2 other companies: KYVERNA THERAPEUTICS, INC. (Aug 2026), CENTURY THERAPEUTICS, INC. (Nov 2025)
- Jennison Associates LLC also filed stake reports on 14 other companies: LENDINGTREE INC (Oct 2026), PALVELLA THERAPEUTICS INC (Oct 2026), REZOLUTE INC (Oct 2026)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
Watch Cabaletta Bio Inc
Get an email when Cabaletta Bio Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cabaletta Bio Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cabaletta Bio Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cabaletta Bio Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
35 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 28,048,173 | 0 | 28,138,417 | 0 | SCHEDULE 13G/A, 2026-11-06 |
| Jennison Associates LLC | 24,267,980 | 0 | 0 | 24,267,980 | SCHEDULE 13G/A, 2026-06-04 |
| Prudential Financial Inc | 0 | 19,465,084 | 0 | 24,267,980 | SCHEDULE 13G/A, 2026-06-05 |
| Bain Capital Life Sciences Opportunities III, LP | 0 | 17,241,445 | 0 | 17,241,445 | SCHEDULE 13G/A, 2026-08-14 |
| Adage Capital Management, L.P. | 0 | 14,174,758 | 0 | 14,174,758 | SCHEDULE 13G/A, 2026-08-12 |
| Robert Atchinson | 0 | 14,174,758 | 0 | 14,174,758 | SCHEDULE 13G/A, 2026-08-12 |
| Phillip Gross | 0 | 14,174,758 | 0 | 14,174,758 | SCHEDULE 13G/A, 2026-08-12 |
| BlackRock, Inc. | 12,756,356 | 0 | 13,013,495 | 0 | SCHEDULE 13G/A, 2026-10-27 |
| Cormorant Asset Management, LP | 0 | 10,000,000 | 0 | 10,000,000 | SCHEDULE 13G/A, 2026-08-14 |
| Bihua Chen | 0 | 10,000,000 | 0 | 10,000,000 | SCHEDULE 13G/A, 2026-08-14 |
| Norges Bank | 8,663,310 | 0 | 4,112,401 | 4,663,252 | SCHEDULE 13G, 2026-08-12 |
| Vanguard Capital Management | 1,042,425 | 0 | 8,187,183 | 0 | SCHEDULE 13G/A, 2026-10-30 |
| Millennium Management LLC | 0 | 2,068,491 | 0 | 2,068,491 | SCHEDULE 13G/A, 2026-07-23 |
| Millennium Group Management LLC | 0 | 2,068,491 | 0 | 2,068,491 | SCHEDULE 13G/A, 2026-07-23 |
| Israel A. Englander | 0 | 2,068,491 | 0 | 2,068,491 | SCHEDULE 13G/A, 2026-07-23 |
The latest filing identifies Cabaletta Bio Inc by CUSIP 12674W109 and gives its principal executive office as 2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA 19104 (SCHEDULE 13G/A, 2026-11-06).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 1% | SCHEDULE 13G/A |
| 2025-07-29 | The Vanguard Group | 3.83% | SCHEDULE 13G/A |
| 2025-08-06 | Jennison Associates LLC | 7.2% | SCHEDULE 13G/A |
| 2025-08-06 | Prudential Financial Inc | 7.4% | SCHEDULE 13G/A |
| 2025-08-11 | Nichtberger Steven | 3.3% | SCHEDULE 13G/A |
| 2025-08-12 | Adage Capital Management, L.P. | 9.99% | SCHEDULE 13G/A |
| 2025-08-14 | Bain Capital Life Sciences Opportunities III, LP | 9.99% | SCHEDULE 13G/A |
| 2025-08-14 | Cormorant Asset Management, LP | 5.47% | SCHEDULE 13G |
| 2025-08-14 | Alyeska Investment Group, L.P. | 9.9% | SCHEDULE 13G |
| 2025-11-05 | Jennison Associates LLC | 8.9% | SCHEDULE 13G/A |
| 2025-11-07 | Prudential Financial Inc | 8.9% | SCHEDULE 13G/A |
| 2025-11-07 | T. Rowe Price Investment Management, Inc. | 9.1% | SCHEDULE 13G/A |
| 2025-11-07 | T. Rowe Price Investment Management, Inc. | 11.3% | SCHEDULE 13G/A |
| 2025-11-14 | Kenneth Griffin | 3.4% | SCHEDULE 13G/A |
| 2025-11-14 | Cormorant Asset Management, LP | 9.99% | SCHEDULE 13G/A |
| 2025-11-14 | Alyeska Investment Group, L.P. | 6.03% | SCHEDULE 13G/A |
| 2026-02-17 | Cormorant Asset Management, LP | 9.28% | SCHEDULE 13G/A |
| 2026-02-17 | Alyeska Investment Group, L.P. | 4.67% | SCHEDULE 13G/A |
| 2026-02-17 | T. Rowe Price Investment Management, Inc. | 10.2% | SCHEDULE 13G/A |
| 2026-02-18 | Millennium Management LLC | 5.3% | SCHEDULE 13G |
| 2026-05-15 | Cormorant Asset Management, LP | 9.03% | SCHEDULE 13G/A |
| 2026-06-04 | Jennison Associates LLC | 11.4% | SCHEDULE 13G/A |
| 2026-06-05 | Prudential Financial Inc | 11.4% | SCHEDULE 13G/A |
| 2026-07-23 | Millennium Management LLC | 1.3% | SCHEDULE 13G/A |
| 2026-07-27 | BlackRock, Inc. | 5.9% | SCHEDULE 13G |
| 2026-07-31 | Vanguard Capital Management | 5.08% | SCHEDULE 13G |
| 2026-08-12 | Adage Capital Management, L.P. | 8.43% | SCHEDULE 13G/A |
| 2026-08-12 | Norges Bank | 5.38% | SCHEDULE 13G |
| 2026-08-14 | Cormorant Asset Management, LP | 5.95% | SCHEDULE 13G/A |
| 2026-08-14 | Bain Capital Life Sciences Opportunities III, LP | 9.99% | SCHEDULE 13G/A |
| 2026-08-14 | T. Rowe Price Investment Management, Inc. | 11.6% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock, Inc. | 7.7% | SCHEDULE 13G/A |
| 2026-10-30 | Vanguard Capital Management | 3.79% | SCHEDULE 13G/A |
| 2026-11-06 | T. Rowe Price Investment Management, Inc. | 8% | SCHEDULE 13G/A |
| 2026-11-06 | T. Rowe Price Investment Management, Inc. | 13.1% | SCHEDULE 13G/A |
Questions about who owns Cabaletta Bio Inc
Who owns Cabaletta Bio Inc?
On this page, 8 holders' latest ownership filings report 5% or more of Cabaletta Bio Inc: T. Rowe Price Investment Management, Inc. (13.1%, Schedule 13G/A, filed 2026-11-06), Jennison Associates LLC (11.4%, Schedule 13G/A, filed 2026-06-04), Prudential Financial Inc (11.4%, Schedule 13G/A, filed 2026-06-05), Bain Capital Life Sciences Opportunities III, LP (9.99%, Schedule 13G/A, filed 2026-08-14) and Adage Capital Management, L.P. (8.43%, Schedule 13G/A, filed 2026-08-12); 3 more are listed above.
Who are the largest shareholders of Cabaletta Bio Inc?
By the share each holder's latest filing reports, the largest holders of Cabaletta Bio Inc on this page are T. Rowe Price Investment Management, Inc. (13.1%), Jennison Associates LLC (11.4%) and Prudential Financial Inc (11.4%).
When did T. Rowe Price Investment Management, Inc. buy into Cabaletta Bio Inc?
The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Investment Management, Inc. on this page is the Schedule 13G/A, filed 2025-11-07, reporting 9.1%; its latest, Schedule 13G/A filed 2026-11-06, reports 13.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 35 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Cabaletta Bio Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.